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Philippe van de Perre and Michel Cartoux 
Transmission of animal retroviruses has been demonstrated both for oncogenic retroviruses and animal lentiviruses. In 
humans, breast-feeding is the major route for mother-to-child transmission of Human T-cell Leukemia/Lymphoma Virus 
type I (HTLV-I). HTLV-I transmission by breast milk is associated with ingestion of infected cells and can be prevented by 
formula-feeding. Breast-feeding transmission of the Human Immunodeficiency Virus type 1 (HIV-1) has only been 
recently recognized as responsible for one to two thirds of mother-to-child transmission in breast-fed populations. 
A primary HIV-1 infection acquired in mothers after the baby has begun breast-feeding is associated with a particularly 
high risk of transmission. Breast milk transmission appears to result from the coexistence of HIV-1 and an inadequate 
humoral response in milk. Due to the dramatic impact of formula-feeding on child morbidity and mortality, it is suggested 
that present recommendation continue to promote breast-feeding in women living in settings where infectious diseases 
and malnutrition are the primary causes of infant deaths, as in many developing countries. On the other hand, in settings 
where infectious diseases and malnutrition are not the primary causes of infant deaths, as in most of the developed 
world, mothers with a proven HIV-1 infection should be advised not to breast-feed their babies. 
Key words: Oncogenic viruses, lentiviruses, HTLV-I, HIV-1, breast milk, colostrum, postnatal transmission, risk factors, 
recommendations. 
The First Part of the Story: 
The Pioneers from Veterinary Medicine 
The first time that breast-feeding was implicated as a 
mode of retroviral transmission was many decades ago. 
Bittner, in an inspired pioneering study, described the 
development of mammary tumors in mice fed milk 
from an affected animal while other offspring deprived 
ofits milk were spared (1). Although revolutionary, this 
investigation by Bittner was not widely publicized, and 
it was only in the early 1960s and in the 1970s that 
the importance of his work became apparent, in the 
perspective of the ever-increasing number of animal 
retroviruses discovered. Bittner’s Mouse Mammary 
Tumor Virus (MMTV), a type B retrovirus responsible 
for mammary adenocarcinomas in susceptible mice, 
was confirmed to be primarily transmissible through 
breast-feeding (2) .  Other murine agents, such as the 
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type C retroviruses known as Murine Leukemia 
Viruses (MLV) were also shown to be transmitted by 
breast milk (3,  4). 
Many of the retroviruses responsible for leukemia 
are transmitted by infected cells (5). For example, in the 
Bovine Leukemia Virus (BLV) model, the virus is 
detectable in milk (6) and can be artificially transmitted 
by oral inoculation of BLV-infected cells (7). Moreover, 
ingestion of milk containing as few as 2000 BLV- 
infected cells is sufficient to contaminate calves (8). 
Inter-species transmission by ingestion of milk has been 
reported in certain conditions. Two newborn chimp- 
anzees fed milk from a cow, which was a heavy excretor 
of BLV, developed erythroleukemia and a Pneurnocystis 
carinii infection (9). 
Colostrum and breast milk are also major routes 
of lentiviral transmission. In the prototype model 
among the lentivirinae, that of slow infection in goat 
and sheep, caused by visna maedi virus and Caprine 
Arthritis Encephalitis Virus (CAEV), the virus is 
directly excreted in milk due to the presence of highly 
productive germinal centers in the mammary gland 
in the immediate vicinity of lactiferous ducts (10). In 
this model, breast milk is an extremely effective route 
of transmission and it has been estimated that almost 
all young animals fed from an infected doe will 
become contaminated (1 1). Infected macrophages in 
colostrum, behaving as Trojan horse (12), are responsible 
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for essentially all infections of lambs by visna maedi 
virus (13) and kids by CAEV (14). Withdrawal of 
colostrum can reduce considerably, if not prevent, 
transmission of visna maedi virus/CAEV (1 5). 
Feline Immunodeficiency Virus (FIV) is a lenti- 
virus, first identified and characterized in 1987, which 
is responsible for an AIDS-like disease in cats (16). FIV 
has been recently isolated from colostrum and breast 
milk samples from FIV-infected queens (17). Both 
queens with a primary FIV infection acquired during 
lactation (1 8) and those infected by FIV before delivery 
transmit the virus postnatally to their offspring by 
breast-feeding. However, in the FIV model, maternal 
anti-body transfer from colostrum, when it occurs, 
appears to be protective against postnatal transmis- 
sion (1 7). 
Human T-cell Leukemia/Lymphoma Virus 
Type-1 (HTLV-1): the Prototype Human Retrovirus 
Transmissible by Breast-feeding (see Table) 
For several decades after the identification of the first 
animal retrovirus by Rous in 19 10, virologists tried to 
identify retroviruses affecting human beings. With the 
MMTV model in mind, some investigated breast milk 
samples from women with breast cancer in the hope of 
identieing a putative oncogenic virus (19, 20) but this 
approach did not yield fruitful results. 
Shortly after the first isolation and characterization 
of a retrovirus implicated in a human disease, the 
Human T-cell Leukemia/Lymphoma Virus type I 
(HTLV-I) (21, 22), which is the etiologic agent of 
Adult T-cell Leukemia (ATL) and of Tropical Spastic 
ParaparedHTLV-I-Associated Myelopathy (TSP/HAM), 
it became evident that mother-to-child transmission of 
the virus plays an important role in the spread of the 
infection. Overall, between 15 and 45% of mothers 
seropositive for HTLV-I transmit the virus to their 
offspring (23, 26). In utero and intra partum trans- 
mission of HTLV-I seems to be uncommon. HTLV-I 
has been detected by Polymerase Chain Reaction 
(PCR) in small copy numbers in 2 of 4 cord blood 
samples from infected mothers (27) but HTLV-I 
antigen was detected in none of 227 cord blood samples 
from seropositive mothers (24). It  is presently believed 
that HTLV-I maternal neutralizing antibodies trans- 
ferred to the fetus in utero can modulate vertical 
transmission of HTLV-I. 
O n  the other hand, there is strong evidence that 
postnatal transmission by breast-feeding is a major 
mode of HTLV-I transmission. HTLV-I has been 
detected by culture and immunofluorescence in 3 of 22 
transition breast milk samples (28) and by P C R  in 8 
of 9 colostrum samples from seropositive mothers (29). 
It  is considered that oral transmission of HTLV-I occurs 
mainly through cell-to-cell contact. One milliliter of 
human mature breast milk from an HTLV-I infected 
mother contains 1000 infected cells (30). HTLV-I 
infection has been experimentally transmitted by 
feeding breast milk from infected mothers to young 
rabbits (31-33) and by oral inoculation of cultured 
mono-nuclear cells from an ATL patient in common 
marmosets (24, 30). These animal models confirmed 
the hypothesis that intact oral or digestive mucosa may 
be a portal of entry for HTLV-I. 
In a retrospective observational study, mother-to- 
child transmission of HTLV-I occurred in 14 of 47 
(30%) breast-fed children, as compared to none of 9 
Table 1 Biological and epidemiological characteristics of human retroviral infections transmissible by breast milk. 
Vim5 HTLV-I (re$ HIV-I (re4 
Rate of viral shedding in milk of 
infected mothers (PCR) more than 80% 20-50% (46, 47) 
Excreted form in milk cell-associated cell-free and cell-associated 
Overall mother-to-child transmission rate 
in breast-fed populations 1545% (23-26) 
Estimated additional risk of transmission 
attributable to breast-feeding 25-30% (24-26,34, 35) 
2448% (39) 
14% (26% if maternal primary 
infection) (51, 52, 55) 
Risk factors for breast-feeding transmission no maternal circulating anti-p40‘”” (34) 
duration of breast-feeding (34) 
no HIV-1 IgM or IgA in mllk (46) 
maternal immune deficiency (46) 
partial breast-feeding? 
Clinical/public health importance only in areas of high endemicity 
unfrequent disease 
pandemic 
fatal disease 
Prevention in areas of high endemicity: screening and 
artificial feeding (35). banked human milk (71, 72) 
WHO/UNICEF consensus 
statement (75) 
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artificially fed infants (24). In addition, in a prospective 
randomized study, a mother-to-child transmission rate 
of 46% (1 1 of 24) was observed in breast-fed infants, as 
against 9% (1 of 11) in artificially fed infants (25, 26). 
The duration of breast-feeding is correlated with the 
risk of transmission. In a Japanese cohort study, 
mother-to-child HTLV-I transmission occurred in 16 
of 58 infants (27.6%) breast-fed for more than 3 months 
and in 2 of 39 infants (5.1%, P=0.012) breast-fed for 
3 months or less (34) In another, more recent study, 
mother-to-child transmission of HTLV-I was sign- 
ficantly reduced by bottle-feeding (35). 
The X gene of HTLV-I encodes p4OfaX, a viral 
regulatory protein, and plays an important role in the 
transcriptional transactivation of the HTLV-I long 
terminal repeat (36). Antibodies directed to p40'"" 
have been suggested to be predictive of HTLV-I 
infectivity (37). In addition, a study performed in 
Okinawa, Japan, demonstrated an association between 
the presence of maternal anti-p40'"" and a high risk of 
HTLV-I transmission among infants breast-fed for 
more than 3 months (34). In Japan and in some other 
areas where HTLV-I infection is endemic, identified 
seropositive mothers are advised not to breast-feed their 
babies. Recently, 11 of 12 suckling white rabbits given 
intraperitoneal administration of HTLV-I immune 
globulins (HTLVIG), as against 8 of 14 controls, were 
shown to have escaped milk-borne transmission of 
HTLV-I (38). If this observation is confirmed, it could 
indicate that a high level of maternal antibodies to 
HTLV-I may protect against in utero, intra partum and 
early post partum transmission and that passive immuno- 
prophylaxis with HTLVIG administered shortly before 
delivery may reduce the risk of transmission. 
Breast-feeding and the Pandemic of Human 
Immunodeficiency Virus Type 1 Infection (HIV-1) 
(see Table) 
It is now well recognized that mother-to-child trans- 
mission of the Human Immunodeficiency Virus type 1 
(HIV-1), the etiologic agent of the Acquired Immuno- 
deficiency Syndrome (AIDS), can occur at three 
stages: in utero, intra partum and postnatally via breast- 
feeding. However, although HIV-1 is closely related to 
animal lentiviruses transmissible by breast-feeding, such 
as CAEV and FIV, the existence of this mode of 
transmission for HIV-1 has long been treated with 
skepticism. 
Even if a standardized methodology is used to 
calculate the rate of mother-to-child transmission of 
HIV-1, a large variation, from 13 to 48% occurs in 
different settings (39). The reasons for these discrep- 
ancies are numerous (40) and include variation in the 
frequency of known determinants of transmission, 
such as maternal immune deficiency, chorioamnionitis, 
vaginal delivery, instrumentation used during labor, 
premature rupture of membranes, prematurity, and 
possibly also low maternal serum vitamin A concen- 
tration, maternal immune response against HIV and 
viral strain characteristics (41-43). However, when 
these rates are compared, a striking difference exists 
between high rates (above 24%) observed in developing 
countries where breast-feeding is the rule and lower 
rates in industrialized countries (below 15%) where 
most HIV-infected mothers are advised to practice 
artificial feeding. It is, therefore, tempting to attribute 
a major role in transmission to breast-feeding. 
HIV type 2 is uncommonly transmitted from 
mother to child (44) and no study of postnatal trans- 
mission of this virus has been reported so far. 
HIV-1 is present in breast milk of HIV-l-infected 
mothers both as cell-associated (45-47) and cell-free 
virus (48). In a study performed in Kigali, Rwanda, 
HIV-1 proviral DNA was detected by PCR in 60 of 
129 (47%) breast milk samples from HIV-l-infected 
mothers collected at day 15 post partum; this rate 
declined to 20 of 96 (21%) samples collected at 6 
months post partum (46). 
HIV-1 transmission through breast-feeding is made 
more likely by a primary maternal HIV infection 
acquired after the baby has started breast-feeding. 
This phenomenon was first explored in a cohort 
study conducted in Kigali, Rwanda between 1988 and 
1991 (49). Of 9 women seroconverting for HIV-1 more 
than three months after delivery, 4 transmitted the virus 
to their child within a three-month period. All 4 
children had repeated negative serological and PCR 
tests before seroconverting, supporting the postnatal 
acquisition of the infection. Other cohort studies have 
confirmed these observations (50). A meta-analysis in- 
cluding the results of five prospective studies (the two 
studies mentioned above included) gave an estimated 
rate of transmission of 26% (95% Confidence Interval 
(CI): 13-39%) in these circumstances (51,SZ). Obviously, 
the extremely high viral burden experienced by 
subjects with a primary infection in the first 6 weeks, 
which is 10 to 200 times higher than baseline viral loads 
measured later in the infectious process (53), explains 
this dramatically high rate of transmission. The same 
relationship with a high viral load in milk may be 
implicated in a reported case of breast milk transmission 
of HIV-1 temporally associated with the occurrence of 
a maternal breast abscess (54). 
Postnatal transmission of HIV-1 through breast- 
feeding also occurs in the absence of maternal primary 
infection. This phenomenon, however, is much more 
difficult to demonstrate because of the difficulty in 
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diagnosing HIV-1 infection early in life. By pooling 
data from 5 observational studies from industrialized 
countries and a case control study from Zaire, and 
comparing the mother-to-child transmission rates in 
breast-fed and artificially fed infants, the estimated 
additional risk of transmission attributable to breast- 
feeding can be assessed as 14% (95% CI: 7-22%) (52). 
Recent reports considering the time of the first positive 
P C R  result in HIV-infected infants who had been 
breast-fed, suggest that breast-feeding may contribute 
one to two thirds of all transmissions from mother to 
child (55, 56). 
Although it is biologically plausible that, as 
observed in animal lentiviral models, most of the 
postnatal transmission occurs early after initiation of 
lactation due to the high cellular content of colo- 
strum and transition milk (57), the exact timing of 
breast-feeding transmission of HIV-1 remains to be 
determined. Of  particular interest are the recent reports 
of late postnatal transmission of HIV-1 by breast- 
feeding. This has indeed been described in children, 
who seroconverted again after having lost maternal 
HIV-1 antibodies for a prolonged period (56, 58-61), 
and could be of particular importance in the design of 
further interventions aimed at reducing mother-to- 
child transmission of HIV-1 in breast-fed infants (62). 
Although the mechanism by which most children 
exposed to HIV-1 during breast-feeding escape con- 
tamination is still mysterious, some protective factors 
against transmission have been identified in breast milk 
of HIV-1-infected mothers. A macromolecular factor 
has been detected in breast milk samples from HIV-1- 
infected mothers, which is able to inhibit the binding 
of HIV-1 gp120 to the CD4 receptor in vitro and so 
impair viral entry into susceptible cells (63). The 
clinical relevance of this observation has not been 
established thus far. Antibodies directed to HIV-1 
have been detected in breast milk from infected 
mothers (46, 64-66). In a cohort study performed in 
Kigali, Rwanda, the specific humoral response toward 
HIV-1 in milk was evaluated in 208 mothers (46). 
Unexpectedly, anti-HIV-1 of the IgA subtype was not 
predominant in breast milk, although associated with a 
low risk of mother-to-child transmission of HIV-1. In 
contrast, anti-HIV-I IgM was frequently detected and 
the persistence of an IgM response for 18 months of 
lactation was associated with a relatively low risk of 
transmission. This suggests that, as in the experimental 
FIV model, transmission of HIV-1 by breast-feeding 
may be the result of the conjunction of the presence of 
the virus in milk and an ineffective maternal mucosal 
immunological response (46). 
As for HTLV-I, a dose-response effect of breast- 
feeding on the risk of transmission of HIV-1 has been 
suggested (67) although this study based on a register 
has been challenged (68). Theoretically, however, the 
type of breast-feeding practiced may be more im- 
portant for transmission than the amount of breast milk 
ingested. I t  is plausible that exclusive breast-feeding 
confers a lower risk of transmission than partial breast- 
feeding due to its optimal immunological protection of 
the infant’s intestinal mucosa (“immuno-logical 
painting”). In contrast to the cytomegalovirus infection 
model where most breast-feeding trans-mission does 
not lead to a symptomatic disease in infants (69), HIV- 
1 infection acquired through breast-feeding is probably 
inexorably fatal, although breast-feeding may slow down 
the clinical course of pediatric HIV-1 infection (70). 
Conclusions: What Can be Done to Prevent 
Breast-feeding Transmission of Human 
Retroviruses? (see Table) 
As already mentioned, identified HTLV-I-infected 
mothers are usually advised against breast-feeding. 
However, most developing countries have a low 
prevalence of HTLV-I-associated disease (ATL or 
TSP/HAM or both), which generally aggregates in 
clusters (71). Consequently, in most settings, screening 
for HTLV-I and prevention of postnatal transmission of 
HTLV-I by breast-feeding is not considered a public 
health priority and prevention of HTLV-I transmission 
from mother to child is out of the question. In areas 
with a high prevalence of HTLV-I infection, such as 
some parts of Japan and the Caribbean, donor milk 
banking may be an option since it has been demon- 
strated that HTLV-I can be denatured by heat (72) and 
by freeze-thawing procedures (73). 
The situation is dramatically different for the 
HIV-1 infection pandemic. With regards to the adverse 
effect of formula-feeding on child health in settings 
where hygiene is not optimal (74), the World Health 
Organization and the United Nations Children’s Fund 
have recommended breast-feeding in settings where 
malnutrition and infectious diseases are important 
causes of infant deaths (75). 
In the future, interventions may be proposed to 
reduce mother-to-infant transmission of HIV-1, in- 
cluding during breast-feeding. Recently, zidovudine 
(ZDV) given to selected HIV-1 -infected pregnant 
women and their neonates has been shown to reduce 
mother-to-child transmission of HIV-1 by nearly two 
thirds (76). Although ZDV given according to the 
AIDS Clinical Trial Group protocol 076 regimen is 
now the norm for women in industrialized countries 
meeting the trial inclusion criteria (77), its applic- 
ability in developing countries remains problematic 
and many questions remain unresolved, such as 
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tolerance, acceptability, affordability, and sustainability 
of this regimen in such a setting (62, 78). Whether a 
short course of ZDV during pregnancy and delivery has 
any effect on breast-fed infants born to HIV-1-infected 
mothers is most uncertain. Information is consistently 
lacking about the passage and concentration of ZDV 
or other antivirals in milk, and their effect on viral load 
in d k .  It is unknown what the effect would be in 
breast-fed children born to ZDV-treated mothers, who 
escaped in utero and intra partum contamination 
because of ZDV prophylaxis. 
Although anti-retroviral compounds have the 
potential to reduce mother-to-child transmission of 
HIV in the future (79), other interventions, more speci- 
fically focused on breast-feeding transmission, should 
not be overlooked. Alternatives to breast-feeding such 
as colostrum withdrawals (80), infant feeding with 
banked pasteurised donor milk (57, 81), or wet nursing 
should be field-tested in certain settings where there are 
reasonable chances that they will be applicable and 
where formula-feeding is not the best option. 
Nevertheless, currently, preventing women of child- 
bearing age from becoming infected with HIV in the 
first place and preventing HIV-infected women from 
becoming pregnant remain the cornerstones of the 
battle against mother-to-child transmission of HIV 
worldwide. 
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